Publications
338
Citations
17,635
Est. group size
~1
Recurring co-author estimate
Active years
58
Publishing since 1969
David W. Haas conducts medical research focused on how a person's genetics affect their response to drugs used for HIV and tuberculosis. His work studies why some patients experience harmful side effects or differing drug levels, using pharmacogenetics (the study of how genes influence drug response) and clinical trials to improve treatment safety and effectiveness. He also investigates immune-genetic factors related to HIV control and vaccine responses.
Publication activity has been variable over the last decade, with peaks around 2020 and 2023-2024 and lower counts in recent years, averaging roughly 9 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil
Human Genetics · 2026
- Joint Bayesian Inference of Genetic Effect Sizes and PK Parameters in Nonlinear Mixed-Effects Models
arXiv (Cornell University) · 2026
- Joint Bayesian Inference of Genetic Effect Sizes and PK Parameters in Nonlinear Mixed-Effects Models
arXiv (Cornell University) · 2026
- A systematic review and network meta-analysis of the use of gabapentinoids perioperatively at the time of cesarean for reducing opioid use.
North American Proceedings in Gynecology & Obstetrics · 2025
- Genetic polymorphisms and adverse reactions to antituberculosis therapy
Pharmacogenomics · 2025
- Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
Pharmacogenetics and Genomics · 2025
- A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
The Lancet Infectious Diseases · 2025
- Case Studies on the Use of LIDAR Data for Hydraulic Modeling of Upstream Fish Passage
River Research and Applications · 2025
- P-465. Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-containing Antiretroviral Therapy
Open Forum Infectious Diseases · 2025
- Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
Open Forum Infectious Diseases · 2025
- Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV
JAMA Cardiology · 2024
- Impact of HLA class I functional divergence on HIV control
Science · 2024
- Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa
British Journal of Clinical Pharmacology · 2024
- Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort
Pharmacogenetics and Genomics · 2024
- Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil
The Journal of Infectious Diseases · 2024
- Pharmacogenetics and Genomics×12
- Clinical Infectious Diseases×11
- The Journal of Infectious Diseases×8
- UNC Libraries×6
- Journal of Antimicrobial Chemotherapy×5
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile